Clinical Experts Discuss Momelotinib for Myelofibrosis: Anemia Utility, Dosing, Safety

Prithviraj Bose, MD, of MD Anderson Cancer Center moderated a discussion panel of myelofibrosis experts composed of Francesca Palandri, MD, PhD, of Università di Bologna, Andrew Kuykendall, MD, of Moffitt Cancer Center, and Lucia Masarova, MD, of MD Anderson Cancer Center. The panel took place at the 66th American Society of Hematology Annual Meeting & Exposition.

The panel’s members expressed encountering high interest among their anemic patients in momelotinib for myelofibrosis and went into detail about specific aspects of its clinical use. Dr. Palandri described ease of dosing with momelotinib and Dr. Kuykendall overviewed the agent’s overall favorable safety profile.